Rubella (German Measles) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

The Rubella virus is transmitted by airborne droplets when infected people sneeze or cough. Its symptoms include fever, headache, stuffy or runny nose, inflamed, red eyes, aching joints and enlarged, tender lymph nodes at the base of the skull, the back of the neck, and behind the ears.

The Rubella pipeline drugs market research report provides comprehensive information on the therapeutics under development for Rubella, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rubella and features dormant and discontinued projects.

Rubella Pipeline Products Market Segmentation by Routes of Administration

The key routes of administration in the Rubella pipeline products market are subcutaneous and intradermal.

Rubella Pipeline Products Market Analysis by Routes of Administration

Rubella Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights into the Rubella pipeline products market, download a free report sample

Rubella Pipeline Products Market Segmentation by Molecule Types

The key molecule types in the Rubella pipeline products market are vaccine, live attenuated vaccine, and subunit vaccine.

Rubella Pipeline Products Market Analysis by Molecule Types

Rubella Pipeline Products Market Analysis by Molecule Types

For more molecule type insights into the Rubella pipeline products market, download a free report sample

Rubella Pipeline Products Market – Competitive Landscape

The leading companies in the Rubella pipeline products market are Beijing Minhai Biotechnology Co Ltd, Amogen Pharma Pvt Ltd, Daiichi Sankyo Co Ltd, Enesi Pharma Ltd, Indian Immunologicals Ltd, Micron Biomedical Inc, Sinovac Biotech Ltd, Vaxxas Inc, Zhongyianke Biotech Co Ltd, and Zydus Lifesciences Ltd.

Rubella Pipeline Products Market Analysis by Companies

Rubella Pipeline Products Market Analysis by Companies

To know more about the leading players in the Rubella pipeline products market, download a free report sample

Rubella Pipeline Products Market Report Overview

Key Routes of Administration Subcutaneous and Intradermal
Key Molecule Type Vaccine, Live Attenuated Vaccine, and Subunit Vaccine
Leading Companies Beijing Minhai Biotechnology Co Ltd, Amogen Pharma Pvt Ltd, Daiichi Sankyo Co Ltd, Enesi Pharma Ltd, Indian Immunologicals Ltd, Micron Biomedical Inc, Sinovac Biotech Ltd, Vaxxas Inc, Zhongyianke Biotech Co Ltd, and Zydus Lifesciences Ltd

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rubella (German Measles) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Rubella (German Measles) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rubella (German Measles) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rubella (German Measles) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Rubella (German Measles) (Infectious Disease)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rubella (German Measles) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rubella (German Measles) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Amogen Pharma Pvt Ltd
Beijing Minhai Biotechnology Co Ltd
Daiichi Sankyo Co Ltd
Enesi Pharma Ltd
Indian Immunologicals Ltd
Micron Biomedical Inc
Sinovac Biotech Ltd
Vaxxas Inc
Zhongyianke Biotech Co Ltd
Zydus Lifesciences Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Rubella (German Measles) – Overview

Rubella (German Measles) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Rubella (German Measles) – Therapeutics Assessment

Assessment by Route of Administration

Assessment by Molecule Type

Rubella (German Measles) – Companies Involved in Therapeutics Development

Amogen Pharma Pvt Ltd

Beijing Minhai Biotechnology Co Ltd

Daiichi Sankyo Co Ltd

Enesi Pharma Ltd

Indian Immunologicals Ltd

Micron Biomedical Inc

Sinovac Biotech Ltd

Vaxxas Inc

Zhongyianke Biotech Co Ltd

Zydus Lifesciences Ltd

Rubella (German Measles) – Drug Profiles

(measles + mumps + rubella + varicella) vaccine – Drug Profile

Product Description

Mechanism Of Action

(measles + mumps + rubella + varicella) vaccine – Drug Profile

Product Description

Mechanism Of Action

(measles + mumps + rubella) vaccine – Drug Profile

Product Description

Mechanism Of Action

(measles + mumps + rubella) vaccine – Drug Profile

Product Description

Mechanism Of Action

(measles + mumps + rubella) vaccine – Drug Profile

Product Description

Mechanism Of Action

(measles + rubella) vaccine – Drug Profile

Product Description

Mechanism Of Action

(measles + rubella) vaccine – Drug Profile

Product Description

Mechanism Of Action

(measles + rubella) vaccine – Drug Profile

Product Description

Mechanism Of Action

(measles + rubella) vaccine – Drug Profile

Product Description

Mechanism Of Action

(measles [strain Edmonstons-Zagreb] + rubella [strain RA-27]) vaccine – Drug Profile

Product Description

Mechanism Of Action

BK-1601 – Drug Profile

Product Description

Mechanism Of Action

rubella vaccine – Drug Profile

Product Description

Mechanism Of Action

VN-0102 – Drug Profile

Product Description

Mechanism Of Action

Rubella (German Measles) – Dormant Projects

Rubella (German Measles) – Product Development Milestones

Featured News & Press Releases

May 05, 2021: Enesi Pharma achieves key milestone in development of thermostable solid-dose live vaccines against measles and rubella

Mar 18, 2020: Vaxxas awarded US$5 million grant for clinical study of measles and rubella vaccination

Nov 30, 2019: Vaxxas was awarded research and development fund of USD 4,997,693 from Bill & Melinda Gates Foundation

Nov 30, 2016: Vaxxas was awarded research and development fund of USD 4,479,552 from Bill & Melinda Gates Foundation

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Rubella (German Measles), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Rubella (German Measles) – Pipeline by Amogen Pharma Pvt Ltd, 2022

Rubella (German Measles) – Pipeline by Beijing Minhai Biotechnology Co Ltd, 2022

Rubella (German Measles) – Pipeline by Daiichi Sankyo Co Ltd, 2022

Rubella (German Measles) – Pipeline by Enesi Pharma Ltd, 2022

Rubella (German Measles) – Pipeline by Indian Immunologicals Ltd, 2022

Rubella (German Measles) – Pipeline by Micron Biomedical Inc, 2022

Rubella (German Measles) – Pipeline by Sinovac Biotech Ltd, 2022

Rubella (German Measles) – Pipeline by Vaxxas Inc, 2022

Rubella (German Measles) – Pipeline by Zhongyianke Biotech Co Ltd, 2022

Rubella (German Measles) – Pipeline by Zydus Lifesciences Ltd, 2022

Rubella (German Measles) – Dormant Projects, 2022

Figures

List of Figures

Number of Products under Development for Rubella (German Measles), 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Rubella (German Measles) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Rubella (German Measles) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Rubella (German Measles) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Rubella (German Measles) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.